- Home
- ICHR vs DNTH Comparison
ICHR vs DNTH Comparison
Compare ICHR & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ICHR | DNTH |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2016 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ICHR | DNTH |
|---|---|---|
| Price | $44.78 | $80.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $45.67 | ★ $123.09 |
| AVG Volume (30 Days) | 636.3K | ★ 1.1M |
| Earning Date | 05-04-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $947,652,000.00 | $2,036,000.00 |
| Revenue This Year | $19.98 | N/A |
| Revenue Next Year | $15.92 | $30.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.61 | N/A |
| 52 Week Low | $13.15 | $13.37 |
| 52 Week High | $55.00 | $88.45 |
Technical Indicators
Market Signals| Indicator | ICHR | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 49.62 | 67.44 |
| Support Level | $15.74 | $33.94 |
| Resistance Level | $55.00 | $88.45 |
| Average True Range (ATR) | 3.39 | 4.60 |
| MACD | -0.34 | -0.43 |
| Stochastic Oscillator | 31.89 | 43.48 |
Price Performance
Historical ComparisonAbout ICHR Ichor Holdings
Ichor Holdings Ltd designs, engineers, and manufactures critical fluid delivery subsystems and components mainly for semiconductor capital equipment, along with solutions for defense/aerospace and medical industries. Its product portfolio includes gas and chemical delivery subsystems that enable precise delivery, monitoring, and control of specialized gases and reactive liquid chemistries used in semiconductor manufacturing processes such as etch, electroplating, and cleaning. The company also provides precision-machined components, weldments, e-beam and laser-welded components, as well as precision vacuum and hydrogen brazing. Geographically, the company operates across the United States, Singapore, Europe, and other regions, with Singapore contributing the majority of revenue.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.